Overview
Ovagen is sold as a peptide bioregulator, variously described by vendors as a gastrointestinal, hepatic or ovarian compound depending on the listing — an inconsistency that is itself a warning sign.
Searching the biomedical literature for Ovagen produces a trap. There are indexed results, but they refer to a completely different product: Ovagen is a commercial follicle-stimulating hormone preparation used in cattle reproduction research, appearing in dairy-cow studies of follicular dynamics at doses like 2.2 mg and 4.4 mg. That is a protein hormone product for veterinary use, not a Khavinson short peptide. Anyone searching for evidence on the peptide will find these papers and may mistake them for supporting research.
No indexed literature for Ovagen as a short peptide bioregulator was located, and no PubChem entry matches the name. Vendor sequences (commonly Glu-Asp-Leu, sometimes Glu-Asp-Leu-Pro) are unconfirmed and disagree on peptide length. PubChem's Glu-Asp-Leu record does not list Ovagen among its synonyms.
What the evidence shows
Separated by study type- HumanClinical trials and human studies
- None located for the short peptide.
- AnimalRodent and other animal models
- Indexed animal studies using the name Ovagen concern a veterinary follicle-stimulating hormone preparation in cattle, an unrelated product.
- In vitroCell and tissue studies
- None located for the short peptide.
Key studies & findings
1 study- 1
Published studies indexed under the name Ovagen concern a commercial FSH preparation administered to dairy cows to induce follicular turnover — an unrelated veterinary product, not a short peptide bioregulator.
Benefits & effects
No benefit data has been compiled for this entry yet.
Side effects & safety
1 reportedSafety noteResearch compound for laboratory use only. No regulatory safety review, no established human safety database, and no controlled toxicology data in the public literature.
Recorded in the cited literature No controlled human safety data exist for this compound · No confirmed chemical identity — material cannot be verified against any public reference.
Name collides with an unrelated veterinary FSH product, inviting citation confusion
Limitations & open questions
No indexed literature exists for Ovagen as a short peptide bioregulator. Search results under this name refer to an unrelated veterinary FSH product, which creates a real risk of citation confusion. The advertised sequence is unconfirmed and vendors disagree on whether it is a tripeptide or a tetrapeptide, as well as on which organ system it targets. There is no public reference against which purchased material can be checked.
Pharmacology
No chemical identity could be confirmed under this name as a short peptide. No molecular formula, molecular weight, CAS number, PubChem CID or pharmacokinetic data are available.
Frequently asked questions
I found published studies on Ovagen — do they support the peptide?
No. Those studies concern a veterinary follicle-stimulating hormone preparation given to dairy cattle to manage follicular waves. It is a different product that happens to share the name. It says nothing about the short peptide sold under the same label.
What is Ovagen's sequence?
Unconfirmed. Vendors list Glu-Asp-Leu or Glu-Asp-Leu-Pro, disagreeing even on peptide length, and PubChem's Glu-Asp-Leu entry does not name Ovagen as a synonym.
Which organ is Ovagen supposed to target?
Vendor listings disagree — gastrointestinal, hepatic and ovarian claims all appear. Inconsistent positioning across sellers is a sign that the claim is not anchored to any source.